Synairgen’s (SNG) shares have pared back by around a third since they hit a record high earlier in the summer, when the small biotech firm revealed positive results for trials of its Covid-19 treatment SNG001. The drug is an inhalable version of interferon beta, a naturally-occurring protein which helps the body’s antiviral responses.
IC TIP:
Hold
at
158p